₹38.00
NSE close, 16 Nov 2026
−36.67%
SAROJA PHARMA INDUS IND L is a small cap company, listed on NSE SME under the symbol SAROJA. At ₹38.00 a share, the market values the whole company at ₹15 crore. NSE SME is the exchange's platform for small and medium companies, which report their results every half year.
In FY26, it reported sales of ₹70 crore and a net profit of ₹2 crore, an operating margin of 5.3%.
The market values the company at 9.7 times its profit over the last twelve months and 0.86 times its book value; its return on equity is 8.8% and its borrowings are 0.90 times its equity.
Promoters hold 73.02% of the shares. Foreign institutions hold 0.00%, and domestic institutions, mutual funds among them, 0.00%.
Over the past year the share price has fallen 11.9%, and it is 12.2% below its 52-week high.
Listed on NSE SME, the platform for small and medium companies: its shares trade in large lots and often thinly, so the price can move sharply on a few trades, and companies file results every half year.
₹ crore. Standalone figures: the company files no consolidated results.
| Line | Sep 2023 | 6M to Mar 2024 | Sep 2024 | 6M to Mar 2025 | 6M to Sep 2025 | 6M to Mar 2026 | 6M to Sep 2026 |
|---|---|---|---|---|---|---|---|
| Sales |
The financial results for the period ended September 30, 2026.
Resignation of M/s Pravin Chandak & Associates, Chartered Accountants as Statutory Auditors of the company w.e.f. November 15, 2026.
Resignation of M/s Pravin Chandak & Associates, Chartered Accountants as Statutory Auditors of the company w.e.f. October 26, 2026.
| 21.1 |
| 19.6 |
| 18.7 |
| 35.0 |
| 38.4 |
| 31.8 |
| 18.4 |
| Expenses | 20.0 | 18.2 | 17.6 | 33.4 | 37.4 | 29.0 | 16.8 |
|---|
| Operating profit | 1.2 | 1.4 | 1.1 | 1.7 | 1.0 | 2.7 | 1.6 |
|---|
| Operating margin | 5.5% | 7.1% | 6.0% | 4.7% | 2.5% | 8.6% | 8.6% |
|---|
| Other income | 0.4 | −0.2 | 0.1 | 0.1 | 0.4 | −0.3 | 0.1 |
|---|
| Interest | 0.8 | 0.6 | 0.7 | 0.7 | 0.5 | 0.9 | 1.0 |
|---|
| Depreciation | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
|---|
| Profit before tax | 0.7 | 0.5 | 0.5 | 1.0 | 0.8 | 1.5 | 0.6 |
|---|
| Tax | 0.2 | 0.1 | 0.1 | 0.3 | 0.2 | 0.4 | 0.1 |
|---|
| Net profit | 0.5 | 0.4 | 0.3 | 0.7 | 0.6 | 1.0 | 0.5 |
|---|
| EPS (₹) | 1.68 | 0.00 | 0.00 | 1.74 | 1.42 | 2.60 | 1.31 |
|---|
₹ crore, financial years to March.
| Line | FY24 | FY25 | FY26 |
|---|---|---|---|
| Sales | 40.7 | 53.7 | 70.1 |
| Expenses | 38.1 | 50.9 | 66.4 |
| Operating profit | 2.6 | 2.8 | 3.7 |
| Operating margin | 6.3% | 5.2% | 5.3% |
| Other income | 0.2 | 0.2 | 0.1 |
| Interest | 1.5 | 1.4 | 1.5 |
| Depreciation | 0.1 | 0.1 | 0.1 |
| Profit before tax | 1.2 | 1.5 | 2.2 |
| Tax | 0.3 | 0.4 | 0.6 |
| Net profit | 0.9 | 1.0 | 1.6 |
| EPS (₹) | 0.00 | 2.57 | 4.02 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY24 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 2.2 | 22.4 | 7.4 | 6.3 |
| From investing | −4.7 | −2.7 | −11.7 | −7.0 |
| From financing | 6.6 | 1.6 | 4.3 | 0.7 |
| Spent on fixed assets | – | −0.1 | −0.2 | −7.0 |
| Free cash flow | – | 22.3 | 7.2 | −0.7 |
Margins, returns, debt, tax and cash.
| Line | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net margin | 2.2% | 1.9% | 2.3% |
| Operating margin | 6.3% | 5.2% | 5.3% |
| Return on equity | – | 6.6% | 9.4% |
| Return on capital employed | – | 11.4% | 11.7% |
| Return on assets | – | 2.6% | 3.9% |
| Debt to equity | – | 0.60 | 0.83 |
| Interest coverage | 1.80 | 2.00 | 2.50 |
| Debt to assets | – | 0.24 | 0.35 |
| Current ratio | – | 1.21 | 1.09 |
| Quick ratio | – | 1.21 | 1.04 |
| Cash ratio | – | 0.01 | 0.02 |
| Asset turnover | – | 1.36 | 1.68 |
| Fixed asset turnover | – | 21.41 | 32.17 |
| Inventory turnover | – | 485.80 | 74.20 |
| Receivables turnover | – | 2.00 | 4.10 |
| Gross margin | – | 9.6% | 9.0% |
| Cash from operations to profit | 250.0% | 2,171.0% | 459.0% |
| Effective tax rate | 27.3% | 28.3% | 27.7% |
Resignation of Mr. Ravindra Shivaji Salaskar as Whole-time Director of the company w.e.f. October 05, 2026.
A copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 30, 2026
Outcome of Board Meeting held on September 25, 2026.
Notice of Annual General Meeting to be held on September 30, 2026
Outcome of Board Meeting held on September 07, 2026.
Significant movement in price has been observed in Saroja Pharma Industries India Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded,…
Outcome of Board Meeting held on August 22, 2026.